share_log

HC Wainwright & Co. Upgrades Kazia Therapeutics to Buy, Announces $2 Price Target

Benzinga ·  Apr 11, 2023 06:21

HC Wainwright & Co. analyst Sean Lee upgrades Kazia Therapeutics (NASDAQ:KZIA) from Neutral to Buy and announces $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment